Top Markets
Coin of the day
Bristol-Myers Squibb Company Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY
Hisse Senetlerindeki Sıralama #174
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity,... Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
Hisse Fiyatı
$62.26
Son senkronizasyon: 2026-09-22
Piyasa Değeri
$127.18B
Değişim (1 gün)
-0.78%
Değişim (1 yıl)
38.63%
Ülke
US
Ticaret Bristol-Myers Squibb Company (BMY)

Kategori

Bristol-Myers Squibb Company (BMY) için temettü geçmişi
Bristol-Myers Squibb Company (hisse sembolü: BMY) toplam 214 temettü ödemesi yaptı.
Tüm temettülerin toplamı (hisse bölünmeleriyle ayarlanmış): $48.98
Temettü verimi (TTM): 0.0392
Bristol-Myers Squibb Company (BMY) için 1972 ile 2026 arasındaki temettü ödemeleri
Yıllık temettü ödemeleri
Yıl Temettü (hisse bölünmesiyle ayarlanmış) Değiştir
2026 (TTM) $0.63 -74.60%
2025 $2.48 3.33%
2024 $2.40 5.26%
2023 $2.28 5.56%
2022 $2.16 46.94%
2021 $1.47 -35.81%
2020 $2.29 39.63%
2019 $1.64 2.50%
2018 $1.60 2.56%
2017 $1.56 36.84%
2016 $1.14 -23.49%
2015 $1.49 2.76%
2014 $1.45 -17.61%
2013 $1.76 29.41%
2012 $1.36 3.03%
2011 $1.32 37.50%
2010 $0.96 -23.20%
2009 $1.25 -19.35%
2008 $1.55 38.39%
2007 $1.12 0.00%
2006 $1.12 0.00%
2005 $1.12 33.33%
2004 $0.84 -25.00%
2003 $1.12 -20.00%
2002 $1.40 32.06%
2001 $1.06 13.65%
2000 $0.9328 13.84%
1999 $0.8194 47.16%
1998 $0.5568 -23.52%
1997 $0.728 -18.64%
1996 $0.8948 69.37%
1995 $0.5283 -39.34%
1994 $0.8709 27.10%
1993 $0.6852 39.10%
1992 $0.4926 -16.87%
1991 $0.5926 13.72%
1990 $0.5211 7.87%
1989 $0.4831 -6.85%
1988 $0.5186 107.52%
1987 $0.2499 16.72%
1986 $0.2141 -4.25%
1985 $0.2236 17.44%
1984 $0.1904 9.43%
1983 $0.174 43.80%
1982 $0.121 14.15%
1981 $0.106 48.46%
1980 $0.0714 -16.59%
1979 $0.0856 18.23%
1978 $0.0724 10.37%
1977 $0.0656 22.39%
1976 $0.0536 9.16%
1975 $0.0491 8.63%
1974 $0.0452 -6.03%
1973 $0.0481 170.22%
1972 $0.0178 0.00%
Tüm temettü ödemelerinin listesi
Yıl Temettü Değiştir
2026 (TTM) $0.63 -74.60%
2025 $2.48 3.33%
2024 $2.40 5.26%
2023 $2.28 5.56%
2022 $2.16 46.94%
2021 $1.47 -35.81%
2020 $2.29 39.63%
2019 $1.64 2.50%
2018 $1.60 2.56%
2017 $1.56 36.84%
2016 $1.14 -23.49%
2015 $1.49 2.76%
2014 $1.45 -17.61%
2013 $1.76 29.41%
2012 $1.36 3.03%
2011 $1.32 37.50%
2010 $0.96 -23.20%
2009 $1.25 -19.35%
2008 $1.55 38.39%
2007 $1.12 0.00%
2006 $1.12 0.00%
2005 $1.12 33.33%
2004 $0.84 -25.00%
2003 $1.12 -20.00%
2002 $1.40 27.27%
2001 $1.10 12.24%
2000 $0.98 -8.84%
1999 $1.08 -8.12%
1998 $1.17 -23.53%
1997 $1.53 -59.31%
1996 $3.76 69.37%
1995 $2.22 -39.34%
1994 $3.66 27.08%
1993 $2.88 39.13%
1992 $2.07 -16.87%
1991 $2.49 13.70%
1990 $2.19 7.88%
1989 $2.03 -6.88%
1988 $2.18 55.71%
1987 $1.40 -22.22%
1986 $1.80 -4.26%
1985 $1.88 17.50%
1984 $1.60 -20.99%
1983 $2.03 -0.49%
1982 $2.04 14.33%
1981 $1.78 48.33%
1980 $1.20 -16.67%
1979 $1.44 18.03%
1978 $1.22 -11.27%
1977 $1.38 -23.61%
1976 $1.80 9.09%
1975 $1.65 8.55%
1974 $1.52 -6.17%
1973 $1.62 170.00%
1972 $0.6 0.00%
Benzer şirketler veya rakipler için temettü ödemeleri
Şirket Temettü ödemesi sayısı Ülke
215.00%
US
225.00%
US
53.00%
US
33.00%
CH
223.00%
US